JB Chemicals & Pharmaceuticals Limited
JBCHEPHARM · Pharma · NSE
₹1,973
Current Market Price
Fair Value (DCF)
₹1,287
Margin of Safety
-34.8%
Updated 17h ago
YieldIQ Score
48/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
34%
ROE
19.2%
Debt/Equity
0.00
WACC
11.0%
Market Cap
₹0.32 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
24.7%
Return on capital employed
EV / EBITDA
26.7×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
84.0×
EBIT covers interest
Current Ratio
3.04×
Short-term liquidity
Asset Turnover
0.88×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.5%
3-year revenue growth
Revenue CAGR (5Y)
15.2%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,973
Bear case
₹785.47
MoS -151.2%
Base case
₹1,286.8
MoS -53.3%
Bull case
₹1,719.16
MoS -14.8%
Ratio Trends
JBCHEPHARM · last 8 annual periods
ROE
19.2%
ROCE
30.9%
Operating Margin
—
Debt / Equity
0.01×
PE
38.7×
EV / EBITDA
22.6×
Historical Financials
JBCHEPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2043 Cr | ₹2424 Cr | ₹3149 Cr | ₹3484 Cr | ₹3862 Cr | +17.3% |
| EBITDA | — | ₹583 Cr | ₹705 Cr | ₹933 Cr | ₹1069 Cr | +16.4% |
| EBIT | ₹604 Cr | ₹510 Cr | ₹591 Cr | ₹796 Cr | — | +7.1% |
| PAT | ₹449 Cr | ₹386 Cr | ₹410 Cr | ₹553 Cr | ₹660 Cr | +10.1% |
| EPS (diluted) | ₹57.96 | ₹49.82 | ₹52.34 | ₹34.85 | — | -11.9% |
| CFO | ₹315 Cr | ₹170 Cr | ₹626 Cr | ₹801 Cr | ₹902 Cr | +30.1% |
| CapEx | — | — | — | — | ₹-120 Cr | — |
| FCF | — | — | — | — | ₹782 Cr | +0.0% |
| Total Assets | — | ₹2607 Cr | ₹3554 Cr | ₹3994 Cr | ₹4274 Cr | +13.1% |
| Total Debt | — | — | ₹165 Cr | ₹334 Cr | ₹27.9 Cr | -35.9% |
| Shareholders' Equity | — | — | ₹2480 Cr | ₹2923 Cr | ₹3433 Cr | +8.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JBCHEPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| EMCURE Emcure Pharmaceuticals Limited | -41.7% | 50 | Above Fair Value | 14.7% | — |
| GLAND Gland Pharma Limited | -12.7% | 64 | Near Fair Value | 7.6% | — |
| AJANTPHARM Ajanta Pharma Limited | -32.4% | 58 | Above Fair Value | 24.3% | — |
| IPCALAB IPCA Laboratories Limited | -22.0% | 56 | Above Fair Value | 8.8% | — |
| WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
17 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹61.58/sh
Last payout
2026-02-11
₹12.70
Peak payout
₹12.70
Trailing yield
1.00%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS) trades at 1973.00 vs a model fair value of 1286.80, a gap of -34.8%. Piotroski F-s...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of JBCHEPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JBCHEPHARM →
Compare
Head-to-head with peers
Compare JBCHEPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JBCHEPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.